Pricing Log in Create free account

IN8bio, Inc. (INAB) vs Moleculin Biotech, Inc. (MBRX)

IN8bio, Inc. and Moleculin Biotech, Inc. are both Biotechnology companies. Moleculin Biotech, Inc. is the larger, with a market value of $9.2M against $8.2M — 1.1× the size. IN8bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.0×. Across the 10 metrics below, IN8bio, Inc. leads on 5 and Moleculin Biotech, Inc. on 5.

Valuation

Metric INAB MBRX Biotechnology median
P/E n/m 0.04 10.26
P/S n/m n/m 9.18
P/B 0.89 0.21 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.08 0.16 0.65
EV/Sales n/m n/m 8.98
Earnings yield (255.95%) 2,573.95% (34.89%)
Free cash flow yield (89.47%) (1,027.71%) (24.52%)

Profitability

Metric INAB MBRX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (111.11%) (1,471.05%) (50.12%)
Return on assets (90.80%) (152.41%) (45.60%)
Return on invested capital (2,948.56%) (417.27%) 0.00%

Growth

Metric INAB MBRX Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) 74.06% 82.01% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INAB MBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.21 0.94 4.89
Net debt to EBITDA 1.56 0.35 1.01

Dividend

Metric INAB MBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INAB MBRX Biotechnology median
Market cap 8.19m 9.16m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack